Effect and safety of theramo -chemotherapy of DDP and 5 -fluorouracil for elderly patients with oral and maxillofacial cancer
10.13699/j.cnki.1001-6821.2015.14.013
- VernacularTitle:顺铂与5－氟尿嘧啶热化疗治疗老年口腔颌面部恶性肿瘤的临床疗效及安全性评价
- Author:
Zi-Ting ZHAO
1
;
Shi-Wen SU
Author Information
1. 丽水市中心医院 口腔科
- Keywords:
oral and maxillofacial cancer;
DDP;
5-fluorouracil;
theramo-chemotherapy;
clinical effect;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2015;(14):1399-1401
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects and safety of theramo-chemotherapy of DDP and 5 -fluorouracil for elderly patients with oral and maxillofacial cancer.Methods Sixty-four patients with oral and maxillofacial cancer were recruited in the prospective study.The patients were randomized divided into control group(n=31) and treatment group ( n=33 ) .Patients in the control group were given DDP 30 mg? m-2 through intravenous drip on day 1 to 3 plus 5-FU 500 mg? m-2 through intravenous drip on day 1 to 5.And patients in the treatment group re-ceived ultrasonic heat with temperature 40-42 ℃, 40 minutes for each time in the period of chemotherapy on the basis of the treatment regime of control group.The treatment lasted for 5 cycles with 21 days a cycle. The data of clinical efficacy, T lymph cell sub -group changes and chemotherapy related adverse drug reactions were compared between the two groups. Results The objective response rate was 29.03% and 57.58%in the control and treatment group respectively, with treatment group significantly higher than the control group(P<0.05).The T cell sub group in the control group were not statistically different before and after treatment ( P>0.05).After treatment, the T cell sub group in treatment group was significantly higher than those of before treatment and control group.And the chemotherapy related adverse drug reactions between the two groups were not statistically different ( 38.71% vs 39.39%, P >0.05 ) . Conclusion DDP and 5-FU theramo-chemotherapy regimen can significantly improve the objective response rate of patients with oral and maxillofacial cancer, but not increasing the risk of developing chemotherapy related adverse drug reactions.
